Broderick Brian C Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

Broderick Brian C grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 125.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,600 shares of the company’s stock after buying an additional 12,000 shares during the period. Broderick Brian C’s holdings in Moderna were worth $2,302,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRNA. Ogorek Anthony Joseph NY ADV acquired a new stake in Moderna during the fourth quarter valued at $27,000. Arlington Trust Co LLC lifted its holdings in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Westside Investment Management Inc. purchased a new position in Moderna during the first quarter valued at $32,000. Rise Advisors LLC lifted its holdings in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in Moderna by 121.8% during the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after purchasing an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 4.6 %

NASDAQ MRNA traded up $5.38 on Thursday, hitting $122.82. 4,162,666 shares of the stock were exchanged, compared to its average volume of 4,133,406. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a market cap of $47.07 billion, a PE ratio of -7.84 and a beta of 1.66. The company has a 50-day moving average price of $135.36 and a 200-day moving average price of $113.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.19 EPS. Sell-side analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 255 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the transaction, the president now directly owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 648 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the completion of the transaction, the chief financial officer now directly owns 5,726 shares in the company, valued at $930,303.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 381,239 shares of company stock worth $52,996,537. 15.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

MRNA has been the topic of several recent analyst reports. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Canaccord Genuity Group lifted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. UBS Group lifted their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Oppenheimer lifted their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $214.00 price target on shares of Moderna in a research report on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $134.02.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.